Genzyme Lowers Target, JDA Cuts Sales Outlook

Established 1999

Global Markets update | Global News | Earnings News | IPO News

Earnings News | Sector Earnings | Earnings Call summaries | Earnings Calendar

IPO Calendar | IPO Profiles | IPO Performance

US Mutual Fund Q&A | US Mutual Fund performance Tables | ETF | Canadian Mutual Fund Q&A

U.S. Government Releases | Economic Release Calendar | Economy charts

Site News Archive Search | Mutual Funds Tables | Annual Reports | 10-K Reports | Same Store sales

123jump.com - U.S. Financial Information Archive: 90,000 Annual and 10-K reports – 20,000 Global news stories - 3,500 IPO reports - 1,700 - Earnings Calls – 320 Fund Interviews – 10-year Annual earnings on 4,500 stocks – 20 Quarterly earnings on 3,600 stocks – 1,800 IPO prospectuses – 1,200 Economic data releases

Earnings Analysis:

Genzyme Lowers Target, JDA Cuts Sales Outlook

Author: Irina Uzunova
123jump.com

Email article | Print article

Genzyme lowers its full-year guidance as soft demand and high inventory levels of its kidney drug Renagel continue to hurt sales. JDA Software cuts software license sales outlook.

More: Earnings Archive

© 1999-2008 123jump.com. All rights reserved	Contact Us \| About Us\| Jobs \| Site Time Line \| Reprints \| Sitemap \| Privacy Policy \| Disclaimer